Ibrutinib and next-generation BTK inhibitors (acalabrutinib, zanubrutinib) can induce a so-called compartment shift of leukemia and lymphoma cells causing egress of malignant lymphocytes deprived of the critical prosurvival signaling from the infiltrated lymph nodes and extra-nodal sites to peripheral blood where the cells eventually die off [123]. The gene discussed is BTK; the disease is lymphoma.